# Phase 5 completion record

- Completion date: 2026-09-18
- Scope: private experimental development
- Accountable owner: joshuamyers22
- Independent numerical/statistical reviewer: Ron Mexico
- Review disposition: Phase 5 scope approved on 2026-09-18

| Required deliverable | Status | Evidence |
|---|---|---|
| `cph`, `psm`, and `npsurv` equivalents | Complete | `PHASE_5_SURVIVAL_ESTIMATORS.md` |
| Ties, strata, entry, weights, offsets, baselines, and residuals | Complete | `PHASE_5_RISK_SETS.md` |
| Survival, hazard, mean, quantile, and curve predictions | Complete | `PHASE_5_PREDICTION_APIS.md` |
| Right-, left-, and interval-censoring where supported | Complete | `PHASE_5_CENSORING.md` |
| Fixed-horizon time-dependent validation primitives | Complete | `PHASE_5_SURVIVAL_VALIDATION.md` |
| Registered survival parity gate | Passed: 16 cases | `reference/cases/`; `tests/test_survival_models.py`; `tests/test_survival_validation.py` |
| Simulation gate | Passed: 7 scenarios and 1,280 replications | `PHASE_5_SIMULATIONS.md` |
| Independent numerical/statistical review | Approved | Ron Mexico, 2026-09-18 |

## Exit-gate disposition

The Phase 5 exit gate passes for private experimental development. Sixteen
survival cases perform 599 exact and 1,071 numeric comparisons against
committed outputs from the pinned R `rms` 8.2-0 oracle. They cover Cox,
Weibull/exponential AFT, Kaplan–Meier, exact/left/right/interval censoring,
risk-set features, baseline quantities, residuals, prediction quantities, and
fixed-horizon validation. All comparisons pass their registered field-aware
tolerance policies.

The locked seven-scenario simulation plan completes all 1,280 replications
without a failed fit or validation and passes its recovery, coverage,
censoring, tie, strata/offset, Kaplan–Meier, and validation thresholds. CI runs
the clean evidence package and repeats it on the accepted Ubuntu 24.04 and
macOS 15 platform matrix.

Ron Mexico independently reviewed the survival likelihoods, observed
information, risk sets, censoring contributions, predictions, validation
metrics, and simulation thresholds and approved the Phase 5 private
experimental scope on 2026-09-18. This satisfies the final Phase 5 exit
criterion. Phase 6 is the next planned phase.

## Promotion boundary and remaining blocks

Phase completion does not promote any capability beyond `experimental`,
authorize consequential use, or authorize external distribution. Independent
verification and legal/license review roles remain unfilled, and stable
capability promotion retains its separate numerical, API, security, and
documentation gates. This review applies only to the declared Phase 5 private
experimental envelope; it does not approve additional survival distributions,
deferred diagnostics, model-refitting validation, Phase 6, or broader `rms`
compatibility claims.
